Publication · Jul 2026
Presentations & Publications
Publication · Jun 2026
Efficacy of acoramidis in ATTR-CM with and without atrial fibrillation: ATTRibute-CM
Presentation · May 2026 · PDF
BBIO-Acoramidis-ESC-HF2026-sTTR variability
Presentation · May 2026 · PDF
BBIO-Acoramidis-ESC-HF2026_NT-proBNP subgroups
Presentation · May 2026 · PDF
BBIO-Acoramidis-ESC-HF2026_MAIC
Presentation · May 2026 · PDF
BBIO-Acoramidis-ESC-HF2026_KCCQ improvement
Presentation · May 2026 · PDF
BBIO-Acoramidis-ESC-HF2026_KCCQ subgroups
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-OLE M54 – sTTR and KCCQ-OS
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-OLE M54-ACM, CVM, and NT-proBNP
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-sTTR Association with KCCQ
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-Survey of Treatment Patterns and Preferences ATTR-CM
Publication · Mar 2026
Long-term durability of acoramidis efficacy: OLE of ATTRibute-CM
Publication · Feb 2026
Acoramidis in ATTR-CM: expanding evidence from ATTRibute-CM
Publication · Feb 2026
Impact of acoramidis on clinical stability: ATTRibute-CM (Bayer/BridgeBio)
Publication · Dec 2025
A plain language review of the ATTRibute-CM study from NEJM
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- D28 sTTR association with CVMCVH
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- Atrial fibrillation at baseline and clinical outcomes
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- ACM and ACMCVH Subgroup Analysis
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- NT-proBNP and Atrial Fibrillation
Presentation · Nov 2025 · PDF
Acoramidis-AHA 2025- ACM and CVH (early HF with and without AF)
Presentation · Nov 2025 · PDF
Acoramidis-AHA 2025- VA Prevalence Geographic Disparities
Presentation · Nov 2025 · PDF
Acoramidis-AHA 2025- Demographic Disparities
Publication · Nov 2025
Efficacy of acoramidis in wild-type and variant ATTR-CM: ATTRibute-CM and OLE
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-VA-Incidence-of-ATTR-CM-by-State
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-Effect-on-CVM_Recurrent-CVH-Cumulative-Incidence-Oral-Presentation
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-Cardiac-Conduction-abnormalities
Publication · Sep 2025
Effect of acoramidis on recurrent and cumulative CV outcomes: ATTRibute-CM
Presentation · Aug 2025 · PDF
BBIO - Acoramidis TTR - ESC 2025 - Stable/Improved NAC at Month 30
Publication · Aug 2025
Contemporary oral medication use and frequency in ATTR-CM
Publication · Jul 2025
Unravelling the myriad physiologic roles of transthyretin
Publication · Jun 2025
Differential binding affinities and kinetics of transthyretin stabilizers
Presentation · May 2025 · PDF
BBIO - Acoramidis TTR - PNS 2025 - Low Transthyretin Is Associated With Severe Comorbidities
Presentation · May 2025 · PDF
BBIO - Acoramidis AG10 TTR - ESC-HF 2025 - Disease Progression Among Patients for ATTR-CM in a Real-world Setting
Presentation · May 2025 · PDF
BBIO - Acoramidis TTR - ESC-HF 2025 - Atrial Fibrillation-related Events in Patients with ATTR-CM in ATTRibute-CM
Presentation · Apr 2025 · PDF
Acoramidis TTR - ACC 2025 - Addition of Another TTR Stabilizer Did Not Further Increase Serum TTR Levels
Presentation · Apr 2025 · PDF
Acoramidis TTR - ACC 2025 - Pre-specified NT-proBNP Sensitivity Analyses
Presentation · Apr 2025 · PDF
Acoramidis TTR - ACC 2025 - Improvements in NYHA Class at Month 30 Versus Placebo
Publication · Apr 2025
Acoramidis for ATTR-CM: OLE long-term follow-up
Presentation · Mar 2025 · PDF
Acoramidis TTR - ACC 2025 -Healthcare Disparities and Diagnostic Trends
Publication · Feb 2025
Comparison of in-clinic 6MWT by conventional method vs wearable sensors
Presentation · Dec 2024 · PDF
Acoramidis - AHA 2024 - Costs and healthcare resource utilization in ATTR-CM exceeds that of non-amyloid heart failure
Presentation · Dec 2024 · PDF
Acoramidis - AHA 2024 - Relationship between CVH and survival in the acoramidis-treated participants within ATTRibute-CM
Presentation · Dec 2024 · PDF
Acoramidis - HFSA 2024 - ATTRibute-CM Post Hoc Recurrent Event Analyses
Presentation · Dec 2024 · PDF
BBIO - Acoramidis - ISA 2024 - Higher risk of mortality in previously hospitalized patients
Presentation · Dec 2024 · PDF
Acoramidis - ISA 2024- Featured research in the ATTR-CM landscape
Presentation · Dec 2024 · PDF
BBIO - Acoramidis - ESC Heart Failure 2024 - EQ-5D Analysis from the ATTRibute-CM Study
Presentation · Dec 2024 · PDF
BBIO - Acoramidis - ESC Heart Failure 2024 - NT-proBNP Insights from the ATTRibute-CM Study
Presentation · Nov 2024 · PDF
BBIO - Acoramidis - ACC 2024 - CMR Imaging Substudy from ATTRibute-CM Phase 3 Study
Presentation · Sep 2024 · PDF
Presentation · Dec 2023 · PDF
Acoramidis - AHA 2023 - Clinical Outcome Improvements
Presentation · Dec 2023 · PDF
Acoramidis - October 2023 - 4 Year Update from OLE Phase 2 Study
Presentation · Dec 2023 · PDF
Acoramidis - ESC 2023 - ATTRibute-CM-Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Publication · Feb 2021
Patient and family experience with ATTR-CM and ATTR-PN: two focus groups
Publication · Jul 2019
Transthyretin stabilization by AG10 in symptomatic ATTR-CM
Publication · Jun 2019
First-in-human study of AG10: phase 1 in healthy volunteers
Publication · Aug 2018
Enthalpy-driven stabilization of TTR by AG10 mimics a protective genetic variant
Publication · May 2013
AG10 inhibits amyloidogenesis and cellular toxicity of V122I transthyretin
Publication · Aug 2011